Objectives/Goals: Substantial evidence supports the use of community engagement in CTS. Yet, there is a lack of empirical basis for recommending a particular level of community engagement over others. We aimed to identify associations between level of community involvement and study process outcomes, focusing on procedures to promote enrollment and inclusion. Methods/Study Population: Using manifest content analysis, we analyzed community engagement (CEn) strategies of studies indexed in ClinicalTrials.gov, focusing on studies 1) associated with 20 medical schools located in 8 southern states in the Black Belt, 2) conducted in 2015–2019, and 3) on 7 topics: cancer, depression, anxiety, hypertension, substance use disorder, cardiovascular disease, and HIV/AIDS. Data source was the ClinicalTrials.gov entry and publication for each study. We categorized each study on level of community involvement as described by the study protocol CTSA Consortium Community Engagement Key Function Committee Task Force on the Principles of Community Engagement continuum. Outcomes included recruitment and representativeness. Other codes included funder type, study phase, study status, and time to enrollment. Results/Anticipated Results: Of 890 studies that met inclusion criteria, only 493 had published findings. 286 studies (58%) met enrollment targets. Only 9 studies described any level of CEn (1 outreach, 3 consult, 1 involvement, 3 collaboration, and 1 shared leadership). Time to enrollment for these 9 studies (mean 28.78 mos.) was shorter than for studies without CEn (mean 37.43 months) (n.s.). CEn studies reached significantly higher enrollment (CEn mean  = 2395.11, non-CEn mean  = 463.93), p Discussion/Significance of Impact: Results demonstrate the substantial effect of CEn on enrollment and inclusion in clinical studies. However, the infinitesimal number of studies that reported CEn did not allow comparisons of level of engagement on the outcomes. Findings highlight ethical questions surrounding the lack of publishing incomplete studies.

In an effort to combat abuse of police powers by the world's most repressive regimes, the United Nations General Assembly adopted a “Body of Principles for the Protection of All Persons under Any Form of Detention or Imprisonment” at a plenary meeting on December 9, 1988. Among other things, these rules declare that “A detained or imprisoned person shall have the right to be visited by and to correspond with, in particular, members of his family and shall be given adequate opportunity to communicate with the outside world, subject to reasonable conditions and restrictions as specified by law or lawful regulations.” Three years later the UN Commisssion on Human Rights created a five member “Working Group” charged with investigating “cases of detention imposed arbitrarily or otherwise inconsistently with the relevant international standards set forth in the Universal Declaration of Human Rights” or in treaties or other international agreements.

Trifludimoxazin is a protoporphyrinogen oxidase (PPO)-inhibiting herbicide currently under development for preplant burndown and soil-residual weed control in soybean [Glycine max (L.) Merr.] and other crops. Greenhouse dose–response experiments with foliar applications of trifludimoxazin, fomesafen, and saflufenacil were conducted on susceptible and PPO inhibitor–resistant (PPO-R) waterhemp [Amaranthus tuberculatus (Moq.) Sauer] and Palmer amaranth (Amaranthus palmeri S. Watson) biotypes. These PPO-R biotypes contained the PPO2 target-site (TS) mutations ΔG210 (A. tuberculatus and A. palmeri), R128G (A. tuberculatus), and V361A (A. palmeri). The resistant/susceptible (R/S) ratios for fomesafen and saflufenacil ranged from 2.0 to 9.2 across all PPO-R biotypes. In contrast, the response of known PPO inhibitor–susceptible and PPO-R biotypes to trifludimoxazin did not differ within each Amaranthus species. In 2017 and 2018, experiments at the Meigs and Davis Purdue Agriculture Centers were conducted in fields with native A. tuberculatus populations composed of 3% and 30% PPO-R plants (ΔG210 mutation), respectively. At Meigs in 2018, A. tuberculatus control following foliar applications of fomesafen, lactofen, saflufenacil, and trifludimoxazin was greater than 95%. When averaged across the other 3 site-years, applications of 25 g ai ha−1 trifludimoxazin resulted in 95% control of A. tuberculatus at 28 DAA, while applications of fomesafen (343 g ai ha−1), lactofen (219 g ai ha−1), or saflufenacil (25.0 or 50 g ai ha−1), resulted in 80% to 88% control. Thus, at these relative application rates, the foliar efficacy of trifludimoxazin was comparable or greater on A. tuberculatus when compared with other commercial PPO inhibitors, even in populations where low frequencies of PPO-R plants exist. The lack of cross-resistance for common PPO2 TS mutations to trifludimoxazin and the level of foliar field efficacy observed on populations containing PPO-R individuals suggest that trifludimoxazin may be a valuable herbicide in an integrated approach for managing herbicide-resistant Amaranthus weeds.

Trifludimoxazin is a novel protoporphyrinogen oxidase (PPO)-inhibiting herbicide currently under development for foliar and residual control of several problematic weeds in preplant applications for soybean production. Field experiments were conducted in 2017 and 2018 to evaluate the foliar efficacy of trifludimoxazin applied alone and in combination with other herbicides on waterhemp, giant ragweed, and horseweed. Foliar applications of trifludimoxazin alone at 12.5 or 25.0 g ai ha−1 were highly efficacious on glyphosate-resistant waterhemp (94% to 99% control) and moderately effective on giant ragweed (78% to 79% control) and resulted in minor efficacy on horseweed (≤20% control). Combinations of trifludimoxazin with glufosinate, glyphosate, paraquat, or saflufenacil remained highly effective (≥91% control) on waterhemp and giant ragweed. All herbicide mixtures with trifludimoxazin applied to horseweed were classified as additive interactions. Greenhouse experiments and Isobole analysis indicated that trifludimoxazin mixtures with glyphosate and glufosinate on waterhemp and giant ragweed were additive. Mixtures of trifludimoxazin + paraquat were slightly antagonistic under greenhouse conditions when applied to either waterhemp or giant ragweed, whereas trifludimoxazin + saflufenacil was synergistic when applied to giant ragweed. Overall, trifludimoxazin applied alone at 12.5 or 25.0 g ha−1 is effective for managing waterhemp and, to an extent, giant ragweed, but not horseweed, in preplant burndown applications. Furthermore, the addition of glufosinate, glyphosate, paraquat, or saflufenacil to applications of trifludimoxazin does not appreciably reduce weed control for these mixtures. As such, applications of trifludimoxazin alone and in combination with these herbicides may be utilized for effective preplant management of several problematic weeds in soybean.

Cereal rye (Secale cereale L.) cover crop and preemergence herbicides are important components of an integrated weed management program for waterhemp [Amaranthus tuberculatus (Moq.) Sauer] and Palmer amaranth (Amaranthus palmeri S. Watson) management in soybean [Glycine max (L.) Merr.]. Accumulating adequate cereal rye biomass for effective suppression of Amaranthus spp. can be challenging in the upper Midwest due to the short window for cereal rye growth in a corn–soybean rotation. Farmers are adopting the planting green system to optimize cereal rye biomass production and weed suppression. This study aimed to evaluate the feasibility of planting soybean green when integrated with preemergence herbicides for the control of Amaranthus spp. under two soybean planting time frames. The study was conducted across 19 site-years in the United States over the 2021 and 2022 growing seasons. Factors included cover crop management practices (“no-till,” “cereal rye early-term,” and “cereal rye plant-green”), soybean planting times (“early” and “late”), and use of preemergence herbicides (“NO PRE” and “YES PRE”). Planting soybean green increased cereal rye biomass production by 33% compared with early termination. Greater cereal rye biomass production when planting green provided a 44% reduction in Amaranthus spp. density compared with no-till. The use of preemergence herbicides also resulted in a 68% reduction in Amaranthus spp. density compared with NO PRE. Greater cereal rye biomass produced when planting green reduced soybean stand, which directly reduced soybean yield in some site-years. Planting soybean green is a feasible management practice to optimize cereal rye biomass production, which, combined with preemergence herbicides, provided effective Amaranthus spp. management. Soybean stand was a key factor in maintaining soybean yields compared with no-till when planting green. Farmers should follow best management recommendations for proper planter and equipment setup to ensure effective soybean establishment under high levels of cereal rye biomass when planting green.

OBJECTIVES/GOALS: Super refractory status epilepticus (SRSE) is associated with high mortality, often due to withdrawal of life sustaining therapy (WLST) based on perceived poor neurological prognosis. Factors influencing decision making are underreported and poorly understood. We surveyed clinicians who treat SRSE to identify factors that influence WLST. METHODS/STUDY POPULATION: Health care providers (HCP), including physicians, pharmacists, and advanced practice providers, who treat SRSE answered a 51-question survey on respondent demographics, institutional characteristics and SRSE management that was distributed though professional societies. Respondents described approaches to prognostication and rated the importance of clinical factors in the management of two hypothetical clinical cases followed by their prediction of recovery potential for the same two cases. Neurointensivists and other HCP responses were compared using descriptive statistics to differentiate group characteristics; a p-value <0.05 was considered significant. Logistical regression models were employed to identify associations between clinician specific factors and prognostication. RESULTS/ANTICIPATED RESULTS: One-hundred and sixty-four respondents were included in the analysis. Compared to other HCPs (neurologists, epileptologists, neurosurgeons, other intensivists; n=122, 74%), neurointensivists (n=42, 26%) [Odds ratio (OR) 0.3, 95% confidence interval (CI) 0.14-0.68), p=.004)] were less likely to use prognostic severity scores and were less likely to prognosticate likelihood of good functional recovery (OR: 0.28 (95% CI: 0.13-0.62), p=.002) compared to non-neurointensivist HCPs, controlling for potential confounders including professional degree, years of experience, country of practice, and annual volume of SRSE cases. There was, however, significant overlap in factors deemed necessary for determining futility in care escalation. DISCUSSION/SIGNIFICANCE: Neurointensivists value similar clinical factors to other HCPs when evaluating medical futility in SRSE but are less likely to predict definitive outcomes. Pending final survey results, future studies aimed at understanding why neurointensivists may be less likely to decisively prognosticate (i.e. avoiding nihilism) in SRSE may be warranted.